Results 61 to 70 of about 2,071 (176)

Measuring success in HS treatment from the physician's and the patient's perspective

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Integrated clinician (HiSCR, IHS4, IHS4‐55, HS‐IGA) and patient (HiSQOL, DLQI) scores, combined with imaging‐based fibrosis and inflammation assessment, redefine treatment success in hidradenitis suppurativa by aligning treat‐to‐target strategies with both inflammatory control and irreversible structural damage.
Georgios Nikolakis, Monika Arenbergerova, Zeljko Mijuskovic, Baoxi Wang, Christos C. Zouboulis   +4 more
wiley   +1 more source

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for bimekizumab

Frontiers in Pharmacology
BackgroundBimekizumab, a humanized monoclonal antibody, exerts its therapeutic effect by inhibiting interleukin-17A/F and is indicated for the treatment of moderate-to-severe plaque psoriasis in adult patients.
Zhuomiao Lin, Xihui Yu, Meiqing Yang, Jialan Xu, Jiahong Zhong   +4 more
doaj   +1 more source

JAK Inhibitors in Psoriatic–Atopic Dermatitis Overlap: A Four‑Case Series

JEADV Clinical Practice, Volume 5, Issue 3, Page 951-955, September 2026.
ABSTRACT Overlap between psoriasis and atopic dermatitis (AD) poses diagnostic and therapeutic challenges; monoclonal antibodies targeting a single axis may improve one component while worsening the other [1]. Janus kinase (JAK) inhibitors act pleiotropically and may provide simultaneous control of psoriatic and eczematous inflammation [2].
Eleonora Bongiovanni, Francois Rosset, Isotta Giunipero di Corteranzo, Lorenzo Bellando, Rebecca Senetta, Simone Ribero, Pietro Quaglino   +6 more
wiley   +1 more source

Bimekizumab Efficacy and Safety in Patients with Psoriatic Arthritis with Substantial Skin and Nail Psoriasis to 1 Year

Dermatology and Therapy
Introduction Individuals with psoriatic arthritis (PsA) and plaque-type psoriasis and nail involvement have more severe disease and worse quality of life than those without. Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin (
Diamant Thaçi, Akihiko Asahina, Wolf-Henning Boehncke, Alice B. Gottlieb, Mark Lebwohl, Richard B. Warren, Heather Edens, Barbara Ink, Rajan Bajracharya, Jason Coarse, Joseph F. Merola   +10 more
doaj   +1 more source

International consensus on dose reduction of biologics for patients with psoriasis: The DR. Delphi study

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 9, Page 1449-1459, September 2026.
Dermatologists worldwide reached consensus on criteria for dose reduction (DR) of biologics for psoriasis resulting in a DR algorithm for adalimumab, etanercept and ustekinumab. DR of IL‐17 and IL‐23 inhibitors was deemed feasible as well. This first international consensus provides essential information for uptake of biologic DR for psoriasis globally.
C. A. M. van Riel, W.‐H. Boehncke, J. L. W. Lambert, P. I. Spuls, L. S. van der Schoot, I. van Ee, E. M. G. J. de Jong, J. M. P. A. van den Reek, on behalf of the eDelphi consortium, M. Elkalioby, L. Fianen, L. Linhares Leite, C. Boesjes, S. Mahil, M. Franco, F. Valenzuela, C. Chaiyabutr, M. A. Lorna, F. Frez, O. Zargari, T. Hillary, H. Oon, L. Skov, M. Gupta, E. Sotiriou, N. Nguyen Loft, R. Ceovic, K. M. G. Klaassen, J. Wikström, C. Zachariae, P. Asawanonda, R. Vender, A. Carvalho, J. Song, C. Lan, J.‐T. Maul, D. Jullien, B. Hidalgo‐Matlock, A. Duvetorp, M. Gkini, D. Ioannidis, W. Veldkamp, J. Hugo, J. Barboza, A. Carugno, A. Londoño‐García, L. Schneller‐Pavelescu Apetrei, M. Ferran, F. Lafuente Urrez, N. Merino, M. Llamas Velasco, L. Puig, M. Bourcier, M. Perez Ferriols, T. Leonidze, D. Armijo, A. Eylenbosch, M. B. A. van Doorn, P. P. M. van Lumig, P. Ghislain, A. Nast, S. Lanssens, E. Sonkoly, D. J. Hijnen, E. M. Baerveldt, P. Gisondi, M. Tjioe, I. Haeck, K. Agerberg, Y. Okubo   +69 more
wiley   +1 more source

Single-Injection Options for Administering a 320 mg Dose of Bimekizumab: 2 mL Safety Syringe and Auto-injector

Dermatology and Therapy
Introduction Bimekizumab has a favourable safety profile and has demonstrated rapid and superior efficacy, compared with placebo, adalimumab, ustekinumab, and secukinumab, in treating psoriasis.
Michael Sebastian, Jerry Bagel, Bengt Hoepken, Bertram Knapp, Ceyhun Bicer, Merran MacPherson, Richard G. Langley   +6 more
doaj   +1 more source

Real-World Experience of Bimekizumab in a Cohort of 109 Patients Over 48 Weeks and Identification of Predictive Factors for an Early Super Response and Risk of Adverse Events [PDF]

Zeno Fratton,1 Stefano Bighetti,2 Luca Bettolini,2 Vincenzo Maione,2 Mariachiara Arisi,2 Cinzia Buligan,1 Giuseppe Stinco,1 Enzo Errichetti1 1Department of Medicine, Institute of Dermatology, University of Udine, Udine, Friuli Venezia-Giulia, Italy ...
Arisi M, Buligan C, Bettolini L, Maione V, Stinco G, Bighetti S, Fratton Z, Errichetti E   +7 more
core  

Sycosis Barbae Treated With Bimekizumab

Australasian Journal of Dermatology
ABSTRACT Sycosis barbae (SB) is a chronic, potentially scarring alopecia that primarily affects the beard. We report a unique case of refractory SB in a 31‐year‐old male successfully treated with bimekizumab, a dual inhibitor of interleukin (IL)‐17A and IL‐17F.
Matiar Madanchi, Riccardo Curatolo, Lorenzo S. Pelloni, Hazem A. Juratli   +3 more
openaire   +2 more sources

Bimekizumab Complete Clearance of Both Skin and Nail Psoriasis: Comparative Efficacy in Phase III/IIIb Studies

Nail psoriasis can have a substantial negative impact on both the physical and emotional well-being of patients, and is a risk factor for psoriatic arthritis.
Warren, Richard B, Nishida, Emi, Gordon, Kenneth B, Merola, Joseph F, Hoepken, Bengt, Strober, Bruce, Thaçi, Diamant, Gisondi, Paolo, López Pinto, José Manuel, Kavanagh, Sarah, Conrad, Curdin   +10 more
core   +1 more source

Bimekizumab for the treatment of hidradenitis suppurativa

Immunotherapy
Hidradenitis suppurativa (HS) is a painful, inflammatory dermatosis involving recurrent abscesses, nodules and tunnels in intertriginous regions. Biologics and other immunomodulators have significantly expanded the treatment options available for HS. Bimekizumab is a monoclonal antibody targeting both interleukin-17A and interleukin-17F, key mediators ...
Rayad B Shams, Christopher J Sayed
openaire   +2 more sources